Please login to the form below

Not currently logged in
Email:
Password:

Melior enters new pharmaceutical collaboration

Melior Discovery signs an agreement with Johnson & Johnson Pharmaceutical Research & Development for use of Melior's proprietary theraTRACE indications discovery platform to identify new indications

US-based drug discovery company Melior Discovery has signed an agreement with Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) for use of Melior's proprietary theraTRACE indications discovery platform to identify new indications for multiple J&JPRD drug candidates.

Financial terms were not disclosed.

Melior's theraTRACE platform is a multiplexed set of integrated in-vivo models which quickly identify previously unknown applications for pharmaceutical compounds. It can be applied to discovery, development stage and marketed agents and has already identified novel indications for a number of development stage drugs.

Dr Andrew Reaume, president and CEO of Melior, said of the agreement: "Our theraTRACE indications discovery platform is already proving its value in our existing collaborations with Merck and Pfizer, as well as in screening for our own drug development efforts. We are delighted to be working with J&JPRD, and we look forward to a productive collaboration."

7th August 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics